Medical Events of Interest and Health-Related Quality of Life in Chronic Lymphocytic Leukemia Patients Initiating Treatment With Bruton's Tyrosine Kinase Inhibitors Acalabrutinib or Ibrutinib
Latest Information Update: 07 Aug 2024
At a glance
- Drugs Acalabrutinib (Primary) ; Anti-CD20 monoclonal antibody (Primary) ; Ibrutinib (Primary)
- Indications Chronic lymphocytic leukaemia
- Focus Adverse reactions; Therapeutic Use
- Sponsors AstraZeneca
- 28 Jul 2023 Planned End Date changed from 15 Oct 2023 to 5 Sep 2024.
- 28 Jul 2023 Planned primary completion date changed from 15 Oct 2023 to 5 Sep 2024.
- 28 Jul 2023 Status changed from recruiting to active, no longer recruiting.